Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALKS NASDAQ:BPMC NASDAQ:RARE NASDAQ:SDGR NASDAQ:ZLAB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALKSAlkermes$28.55+2.4%$28.05$25.17▼$36.45$4.60B0.531.99 million shs1.37 million shsBPMCBlueprint Medicines$129.46$128.90$73.04▼$129.65$8.36B0.891.55 million shsN/ARAREUltragenyx Pharmaceutical$29.11+1.4%$29.00$25.81▼$59.90$2.77B0.211.36 million shs1.68 million shsSDGRSchrodinger$19.65+3.3%$20.03$16.60▼$28.47$1.40B1.79922,185 shs933,035 shsZLABZai Lab$33.00+1.3%$34.58$20.17▼$44.34$3.64B1.04791,592 shs405,831 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALKSAlkermes+2.44%+3.03%-1.04%-1.86%+2.59%BPMCBlueprint Medicines0.00%0.00%0.00%+0.98%+44.92%RAREUltragenyx Pharmaceutical+1.39%-6.79%-0.03%-21.62%-49.55%SDGRSchrodinger+3.26%+4.63%+1.29%-3.96%-0.35%ZLABZai Lab+1.29%+1.60%-6.88%-4.49%+55.51%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALKSAlkermes$28.55+2.4%$28.05$25.17▼$36.45$4.60B0.531.99 million shs1.37 million shsBPMCBlueprint Medicines$129.46$128.90$73.04▼$129.65$8.36B0.891.55 million shsN/ARAREUltragenyx Pharmaceutical$29.11+1.4%$29.00$25.81▼$59.90$2.77B0.211.36 million shs1.68 million shsSDGRSchrodinger$19.65+3.3%$20.03$16.60▼$28.47$1.40B1.79922,185 shs933,035 shsZLABZai Lab$33.00+1.3%$34.58$20.17▼$44.34$3.64B1.04791,592 shs405,831 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALKSAlkermes+2.44%+3.03%-1.04%-1.86%+2.59%BPMCBlueprint Medicines0.00%0.00%0.00%+0.98%+44.92%RAREUltragenyx Pharmaceutical+1.39%-6.79%-0.03%-21.62%-49.55%SDGRSchrodinger+3.26%+4.63%+1.29%-3.96%-0.35%ZLABZai Lab+1.29%+1.60%-6.88%-4.49%+55.51%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALKSAlkermes 2.92Moderate Buy$41.8546.57% UpsideBPMCBlueprint Medicines 2.11Hold$130.000.42% UpsideRAREUltragenyx Pharmaceutical 2.92Moderate Buy$81.50179.97% UpsideSDGRSchrodinger 2.67Moderate Buy$27.8341.65% UpsideZLABZai Lab 2.86Moderate Buy$56.3570.76% UpsideCurrent Analyst Ratings BreakdownLatest BPMC, ALKS, RARE, ZLAB, and SDGR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/9/2025ALKSAlkermesNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$43.009/9/2025ALKSAlkermesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$34.00 ➝ $35.009/9/2025ALKSAlkermesHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$46.009/9/2025RAREUltragenyx PharmaceuticalHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$80.009/5/2025RAREUltragenyx PharmaceuticalCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$105.009/3/2025ALKSAlkermesWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy9/2/2025ALKSAlkermesWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$44.008/25/2025ZLABZai LabJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$52.008/18/2025SDGRSchrodingerMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$28.00 ➝ $19.008/15/2025SDGRSchrodingerCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$35.00 ➝ $20.008/14/2025SDGRSchrodingerBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$25.00(Data available from 9/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALKSAlkermes$1.56B3.03$2.72 per share10.51$9.05 per share3.15BPMCBlueprint Medicines$562.12M14.87N/AN/A$4.70 per share27.54RAREUltragenyx Pharmaceutical$560.23M5.01N/AN/A$2.76 per share10.55SDGRSchrodinger$237.92M6.08N/AN/A$5.78 per share3.40ZLABZai Lab$398.99M9.24N/AN/A$7.68 per share4.30Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALKSAlkermes$367.07M$2.0813.7320.841.5723.15%24.86%17.14%10/23/2025 (Estimated)BPMCBlueprint Medicines-$67.09M-$2.47N/A199.17N/A-27.70%-64.60%-17.22%10/28/2025 (Estimated)RAREUltragenyx Pharmaceutical-$569.18M-$5.53N/AN/AN/A-87.34%-237.48%-37.66%11/4/2025 (Estimated)SDGRSchrodinger-$187.12M-$2.48N/AN/AN/A-76.22%-45.70%-24.81%11/11/2025 (Estimated)ZLABZai Lab-$257.10M-$2.04N/AN/AN/A-49.68%-27.32%-18.85%11/11/2025 (Estimated)Latest BPMC, ALKS, RARE, ZLAB, and SDGR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025ZLABZai Lab-$0.37-$0.37N/A-$0.37$125.66 million$109.98 million8/6/2025Q2 2025SDGRSchrodinger-$0.83-$0.59+$0.24-$0.59$52.03 million$54.76 million8/5/2025Q2 2025RAREUltragenyx Pharmaceutical-$1.27-$1.17+$0.10-$1.17$161.37 million$166.50 million7/29/2025Q2 2025ALKSAlkermes$0.42$0.52+$0.10$0.52$343.20 million$390.66 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALKSAlkermesN/AN/AN/AN/AN/ABPMCBlueprint MedicinesN/AN/AN/AN/AN/ARAREUltragenyx PharmaceuticalN/AN/AN/AN/AN/ASDGRSchrodingerN/AN/AN/AN/AN/AZLABZai LabN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALKSAlkermesN/A3.232.85BPMCBlueprint Medicines1.012.802.75RAREUltragenyx PharmaceuticalN/A2.452.30SDGRSchrodingerN/A3.303.30ZLABZai LabN/A3.122.93Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALKSAlkermes95.21%BPMCBlueprint MedicinesN/ARAREUltragenyx Pharmaceutical97.67%SDGRSchrodinger79.05%ZLABZai Lab41.65%Insider OwnershipCompanyInsider OwnershipALKSAlkermes4.40%BPMCBlueprint Medicines4.21%RAREUltragenyx Pharmaceutical5.50%SDGRSchrodinger21.00%ZLABZai Lab4.96%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALKSAlkermes1,800165.08 million157.82 millionOptionableBPMCBlueprint Medicines64064.58 million61.86 millionOptionableRAREUltragenyx Pharmaceutical1,29496.37 million91.07 millionOptionableSDGRSchrodinger79073.61 million58.15 millionOptionableZLABZai Lab1,869111.76 million106.22 millionOptionableBPMC, ALKS, RARE, ZLAB, and SDGR HeadlinesRecent News About These Companies29,693 Shares in Zai Lab Limited Unsponsored ADR $ZLAB Purchased by Acadian Asset Management LLCSeptember 18 at 3:11 AM | marketbeat.comZai Lab Limited (ZLAB): A Bull Case TheorySeptember 16 at 3:04 PM | finance.yahoo.comZai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Receives Average Rating of "Moderate Buy" from BrokeragesSeptember 15, 2025 | marketbeat.comZai Lab (NASDAQ:ZLAB) Insider Buys $289,100.00 in StockSeptember 14, 2025 | marketbeat.comZai Lab (NASDAQ:ZLAB) Shares Gap Up - Here's What HappenedSeptember 13, 2025 | marketbeat.comZai Lab (NASDAQ:ZLAB) Insider Acquires $289,100.00 in StockSeptember 13, 2025 | insidertrades.comZai Lab (NASDAQ:ZLAB) Shares Gap Down - Here's WhySeptember 12, 2025 | marketbeat.comZai Lab's Double Whammy: Earnings Miss, Phase 3 SetbackSeptember 11, 2025 | benzinga.comWoodline Partners LP Lowers Stock Holdings in Zai Lab Limited Unsponsored ADR $ZLABSeptember 11, 2025 | marketbeat.comZai Lab Limited (ZLAB) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeptember 9, 2025 | seekingalpha.comZai Lab FY2026 EPS Forecast Lowered by Leerink PartnrsSeptember 9, 2025 | marketbeat.comZai Lab FY2026 EPS Forecast Decreased by Leerink PartnrsSeptember 9, 2025 | americanbankingnews.comCubist Systematic Strategies LLC Has $3.38 Million Stock Position in Zai Lab Limited Unsponsored ADR $ZLABSeptember 8, 2025 | marketbeat.comRaymond James Financial Inc. Has $4.55 Million Holdings in Zai Lab Limited Unsponsored ADR $ZLABSeptember 8, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zai Lab ...September 6, 2025 | bakersfield.comBInstitutional investors may overlook Zai Lab Limited's (NASDAQ:ZLAB) recent US$260m market cap drop as long-term gains remain positiveSeptember 6, 2025 | finance.yahoo.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zai Lab Limited - ZLABSeptember 6, 2025 | globenewswire.comZai Lab (NASDAQ:ZLAB) Stock Price Down 5.8% - Here's What HappenedSeptember 5, 2025 | marketbeat.comAmgen’s bemarituzumab loses momentum as survival edge fadesSeptember 5, 2025 | thepharmaletter.comTCanada Pension Plan Investment Board Buys Shares of 262,500 Zai Lab Limited Unsponsored ADR $ZLABSeptember 5, 2025 | marketbeat.comADAR1 Capital Management LLC Has $34 Million Stake in Zai Lab Limited Unsponsored ADR $ZLABSeptember 4, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines3 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025NIO Just Got Its Second Upgrade of the Month, and It’s BigBy Sam Quirke | August 28, 2025Amazon Faces Rare Downgrade—Is the Rally at Risk?By Sam Quirke | September 2, 2025Energy Fuels: Is This America's Most Strategic Stock?By Jeffrey Neal Johnson | September 6, 2025MP Materials: How One Move Redefined the U.S. Magnet Supply ChainBy Jeffrey Neal Johnson | August 27, 2025BPMC, ALKS, RARE, ZLAB, and SDGR Company DescriptionsAlkermes NASDAQ:ALKS$28.55 +0.68 (+2.44%) Closing price 09/18/2025 04:00 PM EasternExtended Trading$28.56 +0.00 (+0.02%) As of 09/18/2025 05:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.Blueprint Medicines NASDAQ:BPMCBlueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.Ultragenyx Pharmaceutical NASDAQ:RARE$29.11 +0.40 (+1.39%) Closing price 09/18/2025 04:00 PM EasternExtended Trading$30.21 +1.10 (+3.78%) As of 04:14 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.Schrodinger NASDAQ:SDGR$19.65 +0.62 (+3.26%) Closing price 09/18/2025 04:00 PM EasternExtended Trading$19.55 -0.10 (-0.53%) As of 04:44 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.Zai Lab NASDAQ:ZLAB$33.00 +0.42 (+1.29%) Closing price 09/18/2025 04:00 PM EasternExtended Trading$33.07 +0.07 (+0.21%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Fed Cut Rates: What Now for the S&P 500 and Equity Markets? Eli Lilly’s Oral GLP-1 Breakthrough Could Change Everything Bloom Energy Booms on AI Power Demand and Analyst Upgrades Can Apple’s iPhone 17 and AI Push Its Stock to New Highs? Why Seagate Is Wall Street's New Favorite AI Infrastructure Play New Catalysts Build Positive Pressure on Intel Stock Oracle to Hit $1 Trillion Valuation in 2025: Here’s Why General Mills Is a Generational Opportunity for Income Investors Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
